Filtered By:
Source: American Heart Journal
Condition: Bleeding
This page shows you your search results in order of date. This is page number 6.
Order by Relevance | Date
Total 167 results found since Jan 2013.
Association of Measured Platelet Reactivity with Changes in P2Y12 Receptor Inhibitor Therapy and Outcomes Following Myocardial Infarction: Insights into Routine Clinical Practice from the TRANSLATE-ACS Study
Conclusions Only one-third of PCI-treated MI patients with high on-clopidogrel platelet reactivity were switched to a more potent P2Y12 receptor inhibitor. Intensification of antiplatelet therapy was associated with lower risk of ischemic events at 1year among HPR patients.
Source: American Heart Journal - February 10, 2017 Category: Cardiology Source Type: research
Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes
Conclusions In patients with ACS on dual antiplatelet therapy, spontaneous major bleeding events seem “prognostically equivalent” to spontaneous ischemic complications. This result allows quantitative comparisons between both actual and predicted bleeding and ischemic risks. Our findings help to better define net clinical benefit of antithrombotic treatments and more accurate estimate mortality following ischemic and bleeding events in patients with ACS.
Source: American Heart Journal - January 25, 2017 Category: Cardiology Source Type: research
Anemia Is Associated With Bleeding and Mortality, but Not Stroke, in Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial
Conclusions Chronic anemia is associated with a higher incidence of bleeding complications and mortality, but not of stroke, in anticoagulated patients with AF. Apixaban is an attractive anticoagulant for stroke prevention in patients with AF with or without anemia.
Source: American Heart Journal - December 21, 2016 Category: Cardiology Source Type: research
A randomized clinical trial comparing long-term clopidogrel vs aspirin monotherapy beyond dual antiplatelet therapy after drug-eluting coronary stent implantation: Design and rationale of the Harmonizing Optimal Strategy for Treatment of coronary artery stenosis-Extended Antiplatelet Monotherapy (HOST-EXAM) trial
Conclusions The HOST-EXAM will be the first large-scale randomized controlled study to directly compare the efficacy and safety of long-term antiplatelet monotherapy beyond DAPT after DES implantation. This study will provide clinical evidence to establish optimal regimen for long-term antiplatelet therapy after DES implantation.
Source: American Heart Journal - December 20, 2016 Category: Cardiology Source Type: research
Acute Coronary Syndrome Quality Improvement in Kerala (ACS QUIK): Rationale and Design for a Cluster Randomized Stepped Wedge Trial
Publication date: Available online 21 December 2016 Source:American Heart Journal Author(s): Mark D. Huffman, P.P. Mohanan, Raji Devarajan, Abigail S. Baldridge, Dimple Kondal, Lihui Zhao, Mumtaj Ali, Donald M. Lloyd-Jones, Dorairaj Prabhakaran Ischemic heart disease is the leading cause of death in India, and there are likely more myocardial infarctions in India than in any other country in the world. We have previously reported heterogeneous care for patients with myocardial infarction in Kerala, a state in southern India, including both gaps in optimal care and inappropriate care. Based on that prior work, limitations ...
Source: American Heart Journal - December 20, 2016 Category: Cardiology Source Type: research
A randomized clinical trial comparing long-term clopidogrel versus aspirin monotherapy beyond dual antiplatelet therapy after drug-eluting coronary stent implantation: Design and rationale of the HOST-EXAM trial
Conclusions The HOST-EXAM will be the first large-scale randomized controlled study to directly compare the efficacy and safety of long-term antiplatelet monotherapy beyond DAPT after DES implantation. This study will provide clinical evidence to establish optimal regimen for long-term antiplatelet therapy after DES implantation.
Source: American Heart Journal - December 9, 2016 Category: Cardiology Source Type: research
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study
Conclusions GALILEO will test the hypothesis that a rivaroxaban-based antithrombotic strategy reduces the risk of thromboembolic complications post-TAVR with an acceptable risk of bleeding compared with the currently recommended antiplatelet therapy–based strategy in subjects without need of chronic oral anticoagulation.
Source: American Heart Journal - November 25, 2016 Category: Cardiology Source Type: research
Interventional left atrial appendage closure vs novel anticoagulation agents in patients with atrial fibrillation indicated for long-term anticoagulation (PRAGUE-17 study)
Conclusion The PRAGUE-17 trial will determine if LAA occlusion is noninferior to treatment with NOAC in moderate- to high-risk AF patients.
Source: American Heart Journal - November 15, 2016 Category: Cardiology Source Type: research
Trial design: Rivaroxaban for the prevention of major cardiovascular events post transcatheter aortic valve replacement: rationale and design of the GALILEO study
Conclusions GALILEO will test the hypothesis that a rivaroxaban-based antithrombotic strategy reduces the risk of thromboembolic complications post-TAVR with an acceptable risk of bleeding compared with the currently recommended antiplatelet therapy-based strategy in subjects without need of chronic oral anticoagulation.
Source: American Heart Journal - October 31, 2016 Category: Cardiology Source Type: research
Prevalence and Outcome of Thrombotic and Embolic Complications in Adults after Fontan Operation
Conclusions TEC was not uncommon; risk factors for TEC were APC and atrial arrhythmias. Most patients were treated successfully with warfarin alone. A second TEC occurred in most patients whose anticoagulation was discontinued because of bleeding events.
Source: American Heart Journal - October 4, 2016 Category: Cardiology Source Type: research
Vitamin K antagonists for stroke prevention in hemodialysis patients with atrial fibrillation: a systematic review and meta-analysis
Conclusion Our meta-analysis revealed a trend for a reduction of the risk of ischemic stroke in hemodialysis patients with AF treated with VKA. The true protective effect may have been underestimated, owing to inclusion of low-risk patients not expected to benefit from anticoagulation and to suboptimal anticoagulation. However, assessment of the overall effect of VKA in hemodialysis patients should also take into account the increased risk of bleeding, in particular of hemorrhagic stroke. Whether new oral anticoagulants provide a better benefit–risk ratio in hemodialysis patients should be the subject of future trials.
Source: American Heart Journal - October 4, 2016 Category: Cardiology Source Type: research
How Well Does Physician Risk Assessment Predict Stroke and Bleeding in Atrial Fibrillation? Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Conclusion Physician-assigned risk showed a graded relationship with outcomes and both physician-based and empirical scores yielded only moderate discrimination. While empirical scores provided valuable risk stratification information (with or without physician judgement), physician-assessment added little to existing scores. These data support the use of empirical scores for stroke and bleeding risk stratification, and the need for novel approaches to risk stratification in this population.
Source: American Heart Journal - August 26, 2016 Category: Cardiology Source Type: research
A comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization: design and rationale of the randomized Elderly-ACS 2 Study
Conclusion The Elderly-ACS 2 study is a multicenter, randomized trial comparing a strategy of dual antiplatelet therapy with a reduced dose of prasugrel with a standard dose of clopidogrel in elderly patients with ACS undergoing percutaneous revascularization. (The Elderly ACS 2 trial: NCT01777503)
Source: American Heart Journal - August 26, 2016 Category: Cardiology Source Type: research
Incidence and risk factors for thromboembolism and major bleeding in patients with mechanical valve prosthesis; a nationwide population-based study
Conclusions In a nationwide cohort study with MHV and high TTR, heart failure and atrial fibrillation did not appear as risk factors of stroke/TE.
Source: American Heart Journal - August 11, 2016 Category: Cardiology Source Type: research
Effect of age on efficacy and safety of vorapaxar in patients with non –ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial
Conclusion Older patients had a greater risk for ischemic and bleeding events; however, the efficacy and safety of vorapaxar in NSTE ACS were not significantly influenced by age.
Source: American Heart Journal - July 20, 2016 Category: Cardiology Source Type: research
